Ceftriaxone + Tazobactam information from DrugsUpdate  

Pharmacodynamics

Pharmacokinetics

Ceftriaxone interferes with the biosynthesis of the peptidoglycan component of the bacterial cell way by binding to and inactivating penicllin-binding proteins (PBPs). Tazobactam is a penicillanic acid sulfone derivative with β-lactamase inhibitory properties. It enhances the activity of β-lactam antibacterials against β-lactamase-producing bacteria.

Distribution
Ceftriaxone: 98% bound to plasma proteins; crosses the blood brain barrier. Tazobactam: About 30% bound to plasma proteins; widely distributed to tissues and body fluids.

Excretion
Ceftriaxone: Elimination half-life is about 8.7 hours; 33-67% removed as unchanged drug. Tazobactam: Removed mainly via kidneys with 80% of an administered dose as unchanged drug.

Ceftriaxone + Tazobactam Indications / Ceftriaxone + Tazobactam Uses

Information Not Available

Ceftriaxone + Tazobactam Adverse Reactions / Ceftriaxone + Tazobactam Side Effects

Superinfection; anaphylaxis; diarrhoea; local reactions; blood dyscrasias; rash, fever, pruritus; elevated transaminases and alkaline phosphatase. GI effects; pseudomembranous colitis; hematologic effects; hypersensitivity reactions; CNS disturbances; hypertension; chest pain; edema; moniliasis; rhinitis; dyspnea; hypotension; ileus; syncope; local Inj site reactions; rigors.

Potentially Fatal: Pseudomembranous colitis; nephrotoxicity.

Precautions

Information Not Available

Special Precautions

History of penicillin allergy; lactation. Consider possibility of pseudomembranous colitis in patients who present with diarrhoea subsequent to the admin of antibacterial agents. Monitor prothrombin time in patients with impaired vit K synthesis or low vit K stores during treatment. Prolonged treatment may result in overgrowth of nonsusceptible organisms. Caution in patients with a history of GI disease, especially colitis. Discontinue treatment in patients who develop signs/symptoms suggestive of gallbladder disease. Not to be used in hyperbilirubinemic neonates, especially prematures.

Other Drug Interactions

Probenecid; aminoglycosides; vecuronium, methotrexate; oral anticoagulants; heparin.

Potentially Fatal: Disulfiram-like reaction with alcohol. Nephrotoxicity with aminoglycosides and furosemide.

Other Interactions

Information Not Available

Dosage

Intravenous
Skin and skin structure infections, Bacterial septicaemia, Urinary tract infections, Lower respiratory tract infections, Intra-abdominal infections, Bacterial meningitis, Bone and joint infections, Community-acquired pneumonia, Uncomplicated gonorrhoea, Pelvic inflammatory disease
Adult: Expressed in terms of ceftriazone/tazobactam: 1000/125 mg once daily or in equally divided doses twice a day. Total daily dose should not exceed 4 g of ceftriaxone. Continue treatment for at least 2 days after the signs and symptoms have resolved. Usual duration: 7-14 days; longer treatment may be needed in more serious infections. For Streptococci pyogenes infections, treatment should continue for at least 10 days.
Child: Expressed in terms of ceftriaxone: Serious infections: 50-75 mg/kg/day, given in divided doses every 12 hours. Total daily dose should not exceed 2 g of ceftriaxone. Continue treatment for at least 2 days after the signs and symptoms have resolved. Usual duration: 7-14 days; longer treatment may be needed in more serious infections. For Streptococci pyogenes infections, treatment should continue for at least 10 days.

Incompatibility
Vancomycin and fluconazole are incompatible with ceftriaxone in admixture.

Food(before/after)

Information Not Available

Ceftriaxone + Tazobactam and Pregnancy

Information Not Available

Ceftriaxone + Tazobactam and Lactation

Caution when used during lactation

Ceftriaxone + Tazobactam and Children

Information Not Available

Ceftriaxone + Tazobactam and Geriatic

Information Not Available

Ceftriaxone + Tazobactam and Other Contraindications

Hypersensitivity to cephalosporins and β-lactamase inhibitors.

Storage

Intravenous
Before reconstitution: Store below 25°C.

Lab interference

Intravenous
Before reconstitution: Store below 25°C.